menu
Preventive Vaccines Market is projected to be worth USD 94 billion by 2030
Preventive Vaccines Market is projected to be worth USD 94 billion by 2030
Although vaccines were solely responsible for the global eradication of smallpox (1980) and polio (2015), several vaccine-preventable diseases, such as measles and mumps, are still a thre at; COVID-19 has been recently added to the list

RootsAnalysis is pleased to announce the publication of its recent study, titled,“Global PreventiveVaccines Market, 2020-2030”.

Thereport features an extensive study of the current market landscape and futureopportunities associated with the preventive vaccine domain. The study alsofeatures a detailed analysis of the key drivers and trends related to thisevolving segment of the pharmaceutical industry. Amongst other elements, thereport includes:

·       A detailed assessment of the current marketlandscape, featuring clinical-stage preventive vaccines.

·       A competitiveness analysis of preventivevaccine developers, featuring insightful pictorial summaries andrepresentations.

·       Elaborate profiles of the key preventivevaccine developers (shortlisted based on a proprietary criterion) across NorthAmerica, Europe and Asia Pacific.

·       An in-depth analysis of the completed,ongoing and planned trials of various preventive vaccines.

·       An overview of the ongoing vaccinedevelopment initiatives for complex conditions, such as COVID-19, Ebola virusdisease, HIV/AIDS, malaria and zika virus infection.

·       An analysis of the investments made in thisdomain, during the period between 2015 and 2020 (till March).

·       A case study on contract manufacturinglandscape for vaccines, featuring the CMOs engaged in this domain.

Adetailed market forecast, featuring analysis of the current and projectedfuture opportunity across key market segments (listed below)

Routeof Administration

·       Intramuscular

·       Subcutaneous

·       Oral

·       Intravenous

·       Others

Typeof Vaccine

·       Pneumococcal Conjugate Vaccine

·       Human Papilloma Virus Vaccine

·       Rotavirus Vaccine

·       Influenza Vaccine

·       MMR Vaccine

·       Tetanus and Diphtheria Booster Vaccine

·       Varicella Vaccine

·       DTaP-Hib-IPV Vaccine

·       DTaP-HepB-Hib-IPV Vaccine

·       Others

Typeof Vaccine API

·       Live, Attenuated Vaccine

·       Inactivated Vaccine

·       Conjugate Vaccine

·       Subunit Vaccine

·       Toxoid Vaccine

·       Others

TargetPatient Population

·       Pediatric Patients

·       Adults

KeyPlayers

·       GlaxoSmithKline

·       Merck

·       Sanofi Pasteur

·       Pfizer

·       Emergent BioSolutions

·       CSL

·       Others

KeyGeographical Regions

·       North America

·       Europe

·       Asia Pacific

·       Rest of the World  

Keycompanies covered in the report

·       Bio Farma

·       Emergent BioSolutions

·       GC Pharma

·       GlaxoSmithKline

·       Janssen

·       Merck

·       Novavax

·       Pfizer

·       Sanofi Pasteur

·       Valneva

EnquiryBefore Purchase:

https://www.rootsanalysis.com/reports/318/request-customization.html    

AboutRoots Analysis

RootsAnalysis is one of the fastest growing marketresearch companies, sharing fresh and independent perspectives in thebio-pharmaceutical industry. The in-depth research, analysis and insights aredriven by an experienced leadership team which has gained many years ofsignificant experience in this sector. If you’d like help with your growingbusiness needs, get in touch at info@rootsanalysis.com

ContactInformation

RootsAnalysis Private Limited

GauravChaudhary

+1(415) 800 3415

Gaurav.Chaudhary@rootsanalysis.com

 

 

AlsoVisit Our Latest Publication

Human Microbiome Market

In Silico / Computer-Aided DrugDiscovery Services Market

Antibody Contract Manufacturing Market

Biopharma Contract Manufacturing Market

Cell Therapy Manufacturing Market